3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
3
Phase 2/3
2
Phase 2
2
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Other hematologic neoplasm
2
Plasma cell
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasms
2
Hematologic Neoplasms
2
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Ovarian Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Lymphoproliferative Disorders
1
Laryngeal Neoplasms
1
Glioma
1
Erdheim-Chester Disease
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cytarabine
25
Cyclophosphamide
23
venetoclax
16
Methotrexate
15
Daunorubicin
14
Dexamethasone
13
Vincristine
11
Etoposide
11
Azacitidine
10
Idarubicin
9
Decitabine
9
Busulfan
9
fludarabine
8
Radiotherapy
8
Prednisone
8
Stem Cell Transplantation
7
Mercaptopurine
7
Doxorubicin
7
Asparaginase
7
pegaspargase
6
fludarabine phosphate
6
blinatumomab
6
Granulocyte Colony-Stimulating Factor
6
Gemtuzumab
6
Filgrastim
6
Thiotepa
5
Methylprednisolone
5
Dasatinib
5
Whole-Body Irradiation
4
Trimethoprim, Sulfamethoxazole Drug Combination
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2/3
×
cobimetinib
×
Other hematologic neoplasm
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled